SRA International Awarded $17.9 Million Task Order to Continue Support of The Cancer Genome Atlas
October 07 2010 - 4:01PM
Business Wire
SRA International, Inc. (NYSE: SRX), a leading provider of
technology and strategic consulting services and solutions to
government organizations and commercial clients, today announced
the award of a task order as a contractor to the National
Institutes of Health (NIH) to continue bioinformatics support of
the Data Coordinating Center (DCC) for The Cancer Genome Atlas
(TCGA). The new award to SRA has a potential total dollar value of
$17.9 million over five years, if all options are exercised.
A joint project of the National Cancer Institute and the
National Human Genome Research Institute, TCGA is one of the
largest collaborative efforts ever attempted for the molecular
characterization of tumors to improve our ability to diagnose,
treat and prevent cancer.
SRA has supported TCGA since its inception as a pilot in 2006.
Based on the remarkable sets of multidimensional data generated by
the pilot, TCGA has expanded from a pilot on two cancers to a full
program to study more than 20 types of cancer. The first 18 months
of this task order are funded under the American Reinvestment and
Recovery Act, to help stimulate the economy through support of
biomedical research.
"TCGA is among the most important projects at NIH,” said SRA
Health Programs Vice President Paul Nedzbala. "By leveraging our
scientific and bioinformatics expertise, information technology,
and innovation, SRA is proud to support the expansion of this
historic, groundbreaking program.”
In addition to continued and expanded support of the DCC and the
TCGA data portal, under the new award SRA will develop a Data
Algorithm Repository, as well as provide direct bioinformatics
support to the TCGA Program Office. As the DCC, SRA is responsible
for collecting, transforming, disseminating, and conducting quality
assurance on all of the research study data generated by more than
60 organizations that make up the TCGA network of laboratories,
universities, cancer centers, and private companies, which all
collaborate on the TCGA program. The DCC efforts since the launch
of the TCGA program in 2006 have included developing and supporting
software that controls data submission, reviewing the data for
quality control, and development of an online data portal to share
the data with research and medical communities and the entire
cancer community. SRA has also contributed to the writing of
several scientific papers characterizing brain and ovarian
tumors.
About SRA International, Inc.
SRA and its subsidiaries are dedicated to solving complex
problems of global significance for government organizations and
commercial clients serving the national security, civil government
and global health markets. Founded in 1978, the company and its
subsidiaries have expertise in such areas as air surveillance and
air traffic management; contract research organization (CRO)
services; cyber security; disaster response planning; enterprise
resource planning; environmental strategies; IT systems,
infrastructure and managed services; learning technologies;
logistics; public health preparedness; public safety; strategic
management consulting; systems engineering; and wireless
integration.
SRA and its subsidiaries employ more than 7,000 employees
serving clients from its headquarters in Fairfax, Va., and offices
around the world. For additional information on SRA, please visit
www.sra.com.
Any statements in this press release about future expectations,
plans, and prospects for SRA, including statements about the
estimated value of the contract and work to be performed, and other
statements containing the words “estimates,” “believes,”
“anticipates,” “plans,” “expects,” “will,” and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements. In addition, the forward-looking statements included in
this press release represent our views as of Oct. 7, 2010. We
anticipate that subsequent events and developments will cause our
views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to Oct. 7,
2010.
Sra (NYSE:SRX)
Historical Stock Chart
From May 2024 to Jun 2024
Sra (NYSE:SRX)
Historical Stock Chart
From Jun 2023 to Jun 2024